Your Article Summary
See Latest ArticlesEmpiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus
Pediatrics, 05/27/09
Elliott DJ et al. - Compared with beta-lactams, clindamycin monotherapy conferred no benefit, whereas trimethoprim-sulfamethoxazole was associated with an increased risk of treatment failure in a cohort of children with nondrained noncultured SSTIs who were treated as outpatients. Even in regions with endemic community-acquired MRSA, beta-lactams may still be appropriate, first-line, empiric therapy for children presenting with these infections.
Related Articles
The treatment of diabetic foot infections: focus on ertapenem
Vascular Health and Risk Management, 11/09/09
Relevance Score: 96%
Does Chlamydia pneumoniae Infection Trigger to Development of Asthma in Wheezy Infants
Journal of Asthma, 11/13/09
Relevance Score: 95%
Urinary tract infection: diagnosis, treatment and prevention
British Journal of Nursing, 10/27/09
Relevance Score: 94%
Pandemic preparedness - Risk management and infection control for all respiratory infection outbreaks
Australian Family Physician, 11/09/09
Relevance Score: 92%
Combating antibiotic resistance in urinary tract infection
Nurse Prescribing, 10/12/09
Relevance Score: 92%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Investigational drugs for hepatitis C
Expert Opinion on Investigational Drugs, 12/15/09
Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid
International Journal of Infectious Diseases, 12/15/09
The efficacy of Echinacea in a 3-D tissue model of human airway epithelium
Phytotherapy Research, 12/15/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09